Thomas Mick, Md, Ms Email & Phone Number

New York, US

• Asset: CT-155, a digital therapeutic for treatment of the negative symptoms of Schizophrenia
• Phase 3, study execution and monitoring; n=432, 70 siteso Protocol CT-155-RCT, amendment 3. 4. And 5; CT Clin Dev lead author o CT-155-RCT SAP development; CT Clin Dev lead with Iqvia, Syneos, and BI biostatso Interim.
• CT Evidence Generation lead for decision making and publications in collaboration with Boehringer-IngelheimAsset: CT-156, a digital therapeutic for treatment for people living with Schizophrenia; This program is.
• Early safety & Efficacy trial design, development & ongoing executiono Protocol, Clin Dev for two feasibility and engagement trials, as well as early protocol development of protocols for CT-156 RCT and CT-156-LTEo SAP.
• Regulatory/Clin Ops Supporto CT-156 Pre-sub submission to CDRH/FDA, CT Clin Dev contributor to submissiono CRO selection for CT-156-RCT, CT Clin Dev representative on selection committee
• CT Evidence Lead in weekly Joint Evidence Meetings/Decisions with Boehringer-Ingelheim

Marietta, Georgia, US

• Late-Stage development: o Protocol co-author, multisite US/International 468 subject, 35 sites, phase 2b pivotal knee OA trial, CBER/FDA approved o Protocol co-author, 75 subject Japanese phase 4 clinical trial.
• Regulatory Support: o 5 Clinical information requests responses to the FDA for approval of the phase 2b trial o Two FDA meetings, participated in two phase2b protocol development meetings with CBER/FDA o IND submission.
• Pharmacovigilance/Drug Safety: o Pharmacovigilance/Drug Safety Program, under CMO guidance, co-developed a completely new PV/Drug Safety Program for MIMEDX with UBC as our CRO partner.o Evaluated 250 historical SAEs.
• Medical Affairs Experience: o Scientific Advisory Board for Knee OA development program, co-created Board and spoke at Scientific Advisory Board Meeting o Spoke at Investor Day meeting on knee OA clinical development.

Colorado Springs, Colorado, US

Member of USA Delegation to the Games of the XXXII Olympiad, TokyoDue to my dual experience as a sports medicine physician and psychiatrist, I was recruited to serve as a mental health officer for the US Olympic Team at the Tokyo 2020 Olympics.

Cleveland, Ohio, US

Academic Clinician and researcher with a dual appointment as a sports medicine physician and a sports psychiatrist in the Departments of Orthopedics and Psychiatry

Washington, DC, US

Psychopharmacologic and behavioral management of mental illness, dementia, Alzheimer’s Disease in veterans

Lake Success, NY, US

Sports medicine and non operative orthopedics

New York, NY, US

Sports Medicine and non operative orthopedics physician at Manhattan Orthopaedics, LLC (private group based at Lenox Hill Hospital)

New York, NY, US

• Conducted psychopharmacology and clinical outcomes research at The Icahn School of Medicine at Mount Sinai. Dr Eric Hollander, MD was my research advisor
• Designed and implemented clinical research protocols, including writing informed consent documents.
• Awarded a young investigator grant and Master's Degree in clinical research.

Washington, DC, US

Staff Internist and Staff Psychiatrist

Inpatient and Outpatient internal medicine physician

Outpatient sports medicine in a private practice

Tamuning, Guam, US

Inpatient and outpatient psychiatry at public hospital

Cleveland, Ohio, US

Fellow in sports medicine

Chicago, Illinois, US

Resident physician in combined internal medicine and psychiatry residency

Albuquerque, New Mexico, US

Internship in Emergency Medicine

Doctor Of Medicine - Md, Medicine

Master Of Science - Ms, Clinical Research

Bachelor Of Science - Bs, Pre-Medicine/Pre-Medical Studies And Philosophy